Phase 1/2Recruiting
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia
- Sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrolment
- 78 planned
- Conditions
- Hyperlipidemia; Mixed
- Interventions
- ARO-DIMERPA; Placebo
- Ages
- adults, older adults
- Registry
- NCT07223658
Full record on ClinicalTrials.gov
From the registry
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
Primary outcomes
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
History
Primary completion expected
Last registry update
Started
Registered